10x Genomics Inc. stocks have been trading up by 9.43 percent after strong single-cell platform demand boosted investor optimism.
Click Here for a Millionaire's POV on Trading TXG
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- 10x Genomics entered a multi-year research collaboration with Cleveland Clinic to deploy its Flex Apex, Xenium, and Atera platforms in advanced bladder cancer biomarker work.
- Barclays lifted its TXG price target from $30 to $40 and kept an Overweight rating, pointing to improving sentiment in life science tools and potential Q2 earnings beats.
- Morgan Stanley raised its TXG target to $37 from $22, sticking with Equal Weight ahead of the next earnings report.
- Citi boosted its TXG target from $24 to $45 while remaining Neutral on the stock, signaling both upside and caution.
- CEO Serge Saxonov sold 30,000 TXG shares for about $1.03M on 2026/06/22, but still controls roughly 1.39M Class A shares.
Live Update At 14:02:30 EDT: On Tuesday, July 14, 2026 10x Genomics Inc. stock [NASDAQ: TXG] is trending up by 9.43%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
TXG has quietly turned into a strong momentum name on the chart. Over the past few weeks, 10x Genomics climbed from the low $30s to close near $45.71 on 2026/07/14. That’s a sharp bounce from the 2026/06/22 close at $32.94 and shows traders are bidding up TXG ahead of the next earnings catalyst.
Intraday action on the last trading day backs that up. TXG opened regular hours around $43, dipped briefly to $42.37, then trended higher with tight five‑minute candles, finishing near the high of the day at $45.71. That kind of grind higher, with higher lows all session, tells traders that dip buyers remain in control.
More Breaking News
- SKHY Stock Whipsaws After Massive $26.5B Nasdaq IPO
- AXTI Stock Surges As AI Wafer Demand And New Deal Ignite Volatility
- OTLK Jumps As FDA Accepts ONS-5010 Review And Nasdaq Risk Fades
- VG Stock Dips As EnBW LNG Deal Collides With EU Rule Risks
Fundamentally, TXG is still a growth story with red ink. Quarterly revenue sits around $150.8M with a strong 69.6% gross margin, but operating income is negative at about -$17M and net income is roughly -$13.5M. Still, 10x Genomics throws off positive operating cash flow of $26.1M and free cash flow of about $24.5M, helped by disciplined capex. With nearly $490.3M in cash and minimal long‑term debt, TXG has room to keep funding R&D and platform expansion while traders focus on top‑line growth and margin trends.
Why Traders Are Watching TXG Now
TXG has caught a rare alignment: bullish news, bullish Street calls, and bullish price action. For momentum traders, that’s exactly the mix to track.
On the strategic side, 10x Genomics locked in a multi‑year collaboration with Cleveland Clinic focused on advanced bladder cancer. The deal puts TXG’s Flex Apex, Xenium, and later Atera platforms directly into high‑end oncology research. For traders, this is not about immediate dollars. It’s about validation. Big‑name institutions only standardize on platforms they believe can drive future diagnostics. That supports the long‑term demand narrative for TXG’s tools.
Wall Street has responded in force. Barclays pushed its TXG price target from $30 to $40 with an Overweight rating, pointing to improving sentiment across life science tools and the chance for in‑line to modest Q2 beats. That tells traders that, at least in Barclays’ view, the worst of the derating phase is behind the group.
Then the heavy hitters followed. Citi jumped its TXG target from $24 to $45, while staying Neutral. Morgan Stanley raised its target from $22 to $37 but kept an Equal Weight stance. The message is subtle but important: analysts now see TXG as more valuable than they did just months ago, but they are not giving it a free pass. Execution and valuation still matter.
In the middle of this, CEO Serge Saxonov sold 30,000 shares for about $1.03M on 2026/06/22. Insider selling often spooks newer traders. But he still controls roughly 1.39M Class A shares, so his exposure to TXG remains significant. For disciplined traders, that sale becomes background noise compared with the bigger signals coming from Cleveland Clinic and the Street.
Conclusion
TXG sits at the crossroads of story and numbers, and that’s where active traders thrive. 10x Genomics is still unprofitable on a GAAP basis, with negative EPS and returns on assets and equity deep in the red. Yet the company is growing revenue, protecting a near‑70% gross margin, and generating positive free cash flow. The balance sheet is clean, with a current ratio near 5.9 and long‑term debt modest relative to equity. That gives TXG time to keep building out its platforms.
On the tape, TXG has broken out from the low‑$30s to the mid‑$40s, backed by rising price targets from Barclays, Citi, and Morgan Stanley. The Cleveland Clinic collaboration gives the story real substance in oncology, while steady intraday bids show traders are willing to chase strength, not just buy fear.
For short‑term players, TXG is now a catalyst‑driven name into earnings, with multiple upgraded targets acting as psychological magnets on the chart. For longer‑term, research‑focused traders, the key is to keep tracking platform adoption and whether revenue growth can eventually flip those margins from negative to positive. This is exactly where meticulous planning matters for active trading. As Tim Bohen, lead trainer with StocksToTrade says, “Preparation is half the trade. By the time the bell rings, my decisions are nearly made.” That kind of preparation helps traders build a watchlist, map key levels, and plan risk before any order is placed.
As Tim Sykes likes to hammer home, “Patterns repeat, but only prepared traders profit from them.” With TXG, that means studying the chart, respecting the recent run, and being ready to cut losses fast if the story or price action breaks, while remembering this is educational, not trading advice.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.